Projected estimates of cancer in Canada in 2022.
Journal
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
ISSN: 1488-2329
Titre abrégé: CMAJ
Pays: Canada
ID NLM: 9711805
Informations de publication
Date de publication:
02 05 2022
02 05 2022
Historique:
accepted:
03
03
2022
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
6
5
2022
Statut:
ppublish
Résumé
Regular cancer surveillance is crucial for understanding where progress is being made and where more must be done. We sought to provide an overview of the expected burden of cancer in Canada in 2022. We obtained data on new cancer incidence from the National Cancer Incidence Reporting System (1984-1991) and Canadian Cancer Registry (1992-2018). Mortality data (1984-2019) were obtained from the Canadian Vital Statistics - Death Database. We projected cancer incidence and mortality counts and rates to 2022 for 22 cancer types by sex and province or territory. Rates were age standardized to the 2011 Canadian standard population. An estimated 233 900 new cancer cases and 85 100 cancer deaths are expected in Canada in 2022. We expect the most commonly diagnosed cancers to be lung overall (30 000), breast in females (28 600) and prostate in males (24 600). We also expect lung cancer to be the leading cause of cancer death, accounting for 24.3% of all cancer deaths, followed by colorectal (11.0%), pancreatic (6.7%) and breast cancers (6.5%). Incidence and mortality rates are generally expected to be higher in the eastern provinces of Canada than the western provinces. Although overall cancer rates are declining, the number of cases and deaths continues to climb, owing to population growth and the aging population. The projected high burden of lung cancer indicates a need for increased tobacco control and improvements in early detection and treatment. Success in breast and colorectal cancer screening and treatment likely account for the continued decline in their burden. The limited progress in early detection and new treatments for pancreatic cancer explains why it is expected to be the third leading cause of cancer death in Canada.
Sections du résumé
BACKGROUND
Regular cancer surveillance is crucial for understanding where progress is being made and where more must be done. We sought to provide an overview of the expected burden of cancer in Canada in 2022.
METHODS
We obtained data on new cancer incidence from the National Cancer Incidence Reporting System (1984-1991) and Canadian Cancer Registry (1992-2018). Mortality data (1984-2019) were obtained from the Canadian Vital Statistics - Death Database. We projected cancer incidence and mortality counts and rates to 2022 for 22 cancer types by sex and province or territory. Rates were age standardized to the 2011 Canadian standard population.
RESULTS
An estimated 233 900 new cancer cases and 85 100 cancer deaths are expected in Canada in 2022. We expect the most commonly diagnosed cancers to be lung overall (30 000), breast in females (28 600) and prostate in males (24 600). We also expect lung cancer to be the leading cause of cancer death, accounting for 24.3% of all cancer deaths, followed by colorectal (11.0%), pancreatic (6.7%) and breast cancers (6.5%). Incidence and mortality rates are generally expected to be higher in the eastern provinces of Canada than the western provinces.
INTERPRETATION
Although overall cancer rates are declining, the number of cases and deaths continues to climb, owing to population growth and the aging population. The projected high burden of lung cancer indicates a need for increased tobacco control and improvements in early detection and treatment. Success in breast and colorectal cancer screening and treatment likely account for the continued decline in their burden. The limited progress in early detection and new treatments for pancreatic cancer explains why it is expected to be the third leading cause of cancer death in Canada.
Identifiants
pubmed: 35500919
pii: 194/17/E601
doi: 10.1503/cmaj.212097
pmc: PMC9067380
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
E601-E607Informations de copyright
© 2022 CMA Impact Inc. or its licensors.
Déclaration de conflit d'intérêts
Competing interests: Ryan Woods reports receiving a research grant from the Michael Smith Foundation for Health Research, and funding from the Canadian Partnership Against Cancer. Donna Turner reports receiving a salary as an employee of CancerCare Manitoba, and funding for travel from the Canadian Cancer Society. Dr. Turner is also a volunteer board member of the Manitoba Tobacco Reduction Alliance. No other competing interests were declared.
Références
J Med Screen. 2021 Jun;28(2):100-107
pubmed: 33241760
Health Rep. 2021 Sep 15;32(9):14-26
pubmed: 34523870
Ann Thorac Surg. 2021 Jun;111(6):1805-1811
pubmed: 33039364
Cancer Med. 2019 Apr;8(4):1826-1834
pubmed: 30791219
Health Promot Chronic Dis Prev Can. 2015 Spring;35 Suppl 1:2-186
pubmed: 26011811
Can J Public Health. 2019 Feb;110(1):62-71
pubmed: 30353502
Can J Public Health. 2018 Dec;109(5-6):700-709
pubmed: 29981110
CMAJ Open. 2018 Jan 4;6(1):E1-E10
pubmed: 29301745
CMAJ. 2020 Mar 2;192(9):E199-E205
pubmed: 32122974
Cancer Res. 2017 Apr 1;77(7):1510-1541
pubmed: 28373404
Prev Med. 2021 Oct;151:106586
pubmed: 34217413
CMAJ. 2014 Nov 4;186(16):1225-34
pubmed: 25349003
Prev Med. 2019 May;122:9-19
pubmed: 31078177
Prev Med. 2019 May;122:81-90
pubmed: 31078176
CMAJ Open. 2017 Sep 6;5(3):E682-E689
pubmed: 28877916